Zhou,J. et al. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 93, 102693 (2024).

Li, C. et al. Global burden and trends of lung cancer incidence and mortality. Chin. Med. J. 136, 1583-1590 (2023).

Khodabakhshi, Z. et al. Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput. Biol. Med. 136, 104752 (2021).

1. Vallis, K. A. & Gill, M. R. The molecular landscape of acquired resistance to first-line EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Br. J.Cancer 116, 1379-1388 (2017).
2. Landi, M. T. et al. Genomic profiling of circulating tumor DNA to predict response to first-line therapy in advanced non-small-cell lung cancer. Clin. Cancer Res. 24, 5423-5431 (2018).
3. Chabon, J.J. et al. association of EGFR exon 19 deletion with response to gefitinib in patients with advanced non-small-cell lung cancer. J. Clin. oncol. 28, 2715-2722 (2010).
4. Rosell, R. et al. Erlotinib versus chemotherapy as first-line treatment for patients with EGFR-mutated advanced non-small-cell lung cancer: results of the TRIBUTE trial. Lancet 378, 546-557 (2011).
5. Zhou, W. et al. Osimertinib plus platinum-based chemotherapy versus chemotherapy alone for first-line treatment of EGFR-mutated non-small-cell lung cancer: FLAURA trial. J. Clin. Oncol. 36,1928-1937 (2018).
6. Park, K. et al. Osimertinib in patients with EGFR-mutated non-small-cell lung cancer who have progressed after first-line EGFR-TKI therapy: a multicenter, open-label, phase II study. J. Thorac. Oncol. 13, 1692-1701 (2018).
7. Stefàno, E. et al. An overview of altered pathways associated with sensitivity to platinum-based chemotherapy in neuroendocrine tumors: Strengths and prospects. Int. J. Mol. Sci. 25, 8568 (2024).
8. Fu, K., Xie, F., Wang, F. & Fu, L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol. 15, 173 (2022).
9. Koulouris,A., Tsagkaris, C., Corriero, A. C., Metro, G. & Mountzios, G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: From mechanisms to new therapeutic strat

1. Mok,T. S. et al. Gefitinib or carboplatin-paclitaxel, plus best supportive care, in non-small-cell lung cancer with EGFR-activating mutations. N. Engl. J. med. 361, 947-957 (2009).
2. Rosell, R. et al. Erlotinib versus chemotherapy as first-line treatment in European patients with EGFR-mutated non-small-cell lung cancer (EFEL trial). Ann. Oncol. 22, 1289-1297 (2011).
3. Maemondo,M. et al. Afatinib versus gefitinib in patients with EGFR mutation-positive non-small-cell lung cancer: a randomised, open-label phase III trial. Lancet Oncol. 16, 1345-1354 (2015).
4. Park, K. et al. osimertinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1823-1833 (2015).
5. Jänne, P. A. et al. Osimertinib versus platinum-based chemotherapy in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 378,2189-2202 (2018).
6. Zhou, W. et al. Predictive biomarkers for EGFR-TKI therapy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 118, 127-136 (2018).
7. Wu,Y. L. et al. Association between EGFR mutation status and survival in patients with advanced non-small-cell lung cancer treated with first-line chemotherapy. J. Thorac. Oncol. 3, 858-864 (2008).
8. Sequist, L.V.et al. Resistance to EGFR tyrosine kinase inhibitors in lung cancer: mechanisms and implications. Clin. Cancer Res. 13, 4531-4539 (2007).
9. Pao, W. et al. Acquired resistance to gefitinib in patients with non-small-cell lung cancer due to mutations in the EGFR kinase domain. N. Engl. J.Med. 358, 2177-2187 (2008).
10. Engelke, C. et al. MET amplification and EGFR tyrosine kinase inhibitor sensitivity in non-small-cell lung cancer. Clin. Cancer Res. 17, 6059-6068 (2011).
11. Sequist, L. V., Heymach, J. V., Bell, D. W., Sharma, S. & Pao, W. Predictive biomarkers for EGFR-targeted therapies in non-small-cell lung cancer. J. Clin. Oncol. 26, 5858-5866 (2008).
12. Ohsaki, Y. O. et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7, 603-610 (2000).
13. Liu, T. C., Jin, X., Wang, Y. & Wang, K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am. J. Cancer Res. 7, 187-197 (2017).
14. Batra,U., Biswas, B., prabhash, K. & Krishna, M. V. Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 L858R EGFR mutation-positive adenocarcinoma non-sm.

Li, X. et al. Traditional uses, phytochemistry, and pharmacology of A.altissima (Mill.) swingle bark: a thorough review. J. Ethnopharmacol. 275,114121 (2021).Caramelo, D. et al. Insights into the bioactivities and chemical analysis of A. altissima (Mill.) swingle. Appl. Sci. 11, 11331 (2021).

Wang, R. et al. Antitumor activity of the A. altissima bark phytochemical ailanthone against breast cancer MCF-7 cells. Oncol. Lett. 15, 6022-6028 (2018).

References

25. Alegaon, SG. Design,synthesis and molecular dynamics simulations of thiazole-based hydrazones targeting MDA-MB-231 breast cancer cells. Bioorg. Chem. 157 (2025).

26. Tang, Z.,li,C.,Kang,B., Gao, G. & Zhang, Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98-W102 (2017).

27. Friesner, R. A. et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177-6196 (2006).

Hendriks, L. E.et al. non-small-cell lung cancer. Nat. Rev.dis. Primers. 10, 71 (2024).

Shankar,A. et al. Environmental and occupational determinants of lung cancer. Transl. Lung Cancer Res. 8, S31 (2019).

kerr,K. M. Personalized medicine for lung cancer: New challenges for pathology. Histopathology 60, 531-546 (2012).

“`html

How Gut Bacteria Can fight Cancer

for years, scientists have known that the trillions of bacteria living in our gut – called the gut microbiome – play a big role in our health. Now, research shows these tiny organisms may also be powerful allies in the fight against cancer.

How Gut Bacteria Help

The gut microbiome isn’t just about digestion. It influences our immune system, metabolism, and even our brain function. HereS how it can impact cancer:

• Boosting the Immune System: Some gut bacteria help train our immune cells to recognize and attack cancer cells. A strong immune system is key to fighting off cancer.
• Producing Helpful Substances: Bacteria can create substances like short-chain fatty acids (SCFAs). SCFAs, like butyrate, can help protect against cancer by reducing inflammation and even killing cancer cells.
• Improving Chemotherapy Effectiveness: Certain bacteria can make chemotherapy drugs work better. They do this by changing the drugs into more active forms within the tumor.
• Reducing Inflammation: Chronic inflammation can contribute to cancer advancement. A healthy gut microbiome can help keep inflammation under control.

Specific Bacteria and Cancers

Research is ongoing, but studies have linked specific bacteria to better outcomes in certain cancers:

• Akkermansia muciniphila: This bacterium has been linked to improved responses to immunotherapy in people with lung cancer. Read more
• Faecalibacterium prausnitzii: Found in higher amounts in people who respond well to chemotherapy for colorectal cancer.
• Bifidobacterium: Some types of Bifidobacterium can boost the immune response against melanoma, a type of skin cancer. Read more
• Pseudomonas aeruginosa: Research suggests this bacteria can definitely help fight lung cancer. Read more

How to Improve Your Gut Health

You can take steps to support a healthy gut microbiome:

• Eat a Diverse Diet: Focus on fruits, vegetables, whole grains, and legumes. Different foods feed different types of bacteria.
• Include Fermented Foods: Yogurt, kefir, sauerkraut, and kimchi contain live bacteria that can benefit your gut.
• Limit Processed Foods, Sugar, and Artificial Sweeteners: These can harm beneficial bacteria.
• Consider Probiotics: Probiotic supplements can add beneficial bacteria to your gut, but talk to your doctor before starting any new supplement.
• Avoid Unneeded antibiotics: Antibiotics kill both good and bad bacteria. Use them only when necessary.

The Future of Cancer Treatment

Researchers are exploring ways to directly use gut bacteria in cancer treatment. This includes:

• Fecal Microbiota Transplantation (FMT): Transferring gut bacteria from a healthy donor to a patient.
• Developing “Smart” Bacteria: Engineering bacteria to specifically target and destroy cancer cells.
• Personalized Microbiome-Based Therapies: Tailoring treatments based on a person’s unique gut microbiome.

While